<div id="readability-page-1"><p>09:13 AM EST, 01/02/2026 (MT Newswires) -- Conduit Pharmaceuticals (CDT) said Friday that it has engaged NJS Foresight Bio-Advisor to identify, source, and support out-licensing deals for in its patent portfolio.</p><p>The hiring is meant to expand CDT's commercial reach and speed up potential licensing and royalty deals for its cocrystals and salts, which are meant to improve the solubility, bioavailability and alternative delivery modes of medicines, the company said.</p> <p>MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</p></div>

<p>2026 年 1 月 2 日东部时间上午 9:13（MT Newswires）-- Conduit Pharmaceuticals（CDT）周五表示，已聘请 NJS Foresight Bio-Advisor 来识别、获取并支持其专利组合的外部授权交易。该聘用旨在扩大 CDT 的商业覆盖范围，并加快其共晶体和盐类的潜在授权和版税交易，这些产品旨在改善药物的溶解度、生物利用度和替代给药方式，公司表示。MT Newswires 不提供投资建议。未经授权的复制是严格禁止的</p>

导管制药公司聘请 NJS Foresight 生物顾问以拓展交易